Previous 10 | Next 10 |
home / stock / iphyf / iphyf news
Innate Pharma S.A. (IPHA) Q3 2021 Results Earnings Conference Call November 16, 2021, 08:00 AM ET Company Participants Mondher Mahjoubi - Chairman of Executive Board and Chief Executive Officer Joyson Karakunnel - Executive Vice President and Chief Medical Officer Yannis Morel - Executive Vic...
The following slide deck was published by Innate Pharma S.A. in conjunction with their 2021 Q3 earnings call. For further details see: Innate Pharma S.A. 2021 Q3 - Results - Earnings Call Presentation
Innate Pharma S.A. (IPHYF) Q2 2021 Earnings Conference Call September 15, 2021 08:00 AM ET Company Participants Mondher Mahjoubi - Chairman of Executive Board & CEO Joyson Karakunnel - EVP & Chief Medical Officer Frédéric Lombard - SVP, Chief Financial Officer Henry Wheeler ...
The following slide deck was published by Innate Pharma S.A. in conjunction with their 2021 Q2 earnings call. For further details see: Innate Pharma S.A. 2021 Q2 - Results - Earnings Call Presentation
Innate Pharma S.A. (IPHYF) Q1 2021 Earnings Conference Call May 11, 2021 09:00 AM ET Company Participants Mondher Mahjoubi - Chairman of Executive Board & CEO Joyson Karakunnel - Executive VP & Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Daina Gray...
Innate Pharma SA (IPHYF) Q4 2019 Results Conference Call March 10, 2020 09:00 AM ET Company Participants Danielle Spangler - Head of Investor Relations Mondher Mahjoubi - Chairman of the Executive Board and Chief Executive Officer Dr. Pierre Dodion - EVP and Chief Medical Office...
Innate Pharma ( OTCPK:IPHYF ) has priced its initial public offering by way of a capital increase of 12.5M new ordinary shares, consisting of 8,047,227 ordinary shares in the form of ADSs at $5.50/ADS, and a concurrent private placement of 4,452,773 ordinary shares in E...
Innate Pharma SA (IPHYF) Q2 2019 Results Conference Call September 13, 2019 08:00 AM ET Company Participants Danielle Spangler - Head, IR Mondher Mahjoubi - Chairman and CEO Dr. Pierre Dodion - Chief Medical Officer Jennifer Butler - EVP and U.S. General Manager Laure-Hé...
Innate Pharma S.A. (IPHYF) Q4 2018 Results Earnings Conference Call March 20, 2019 09:00 AM ET Company Participants Danielle Spangler - Investor Relations Mondher Mahjoubi - Chairman of the Executive Board and Chief Executive Officer Laure-Hélène Mercier - Executive...
Innate Pharma ( OTCPK:IPHYF ) has licensed the US and EU commercial rights of AstraZeneca’s (NYSE: AZN ) FDA approved medicine for Hairy Cell Leukemia (HCL), Lumoxiti, marking the first step of its strategy to become a fully integrated company. More news on: Innate Pharm...
News, Short Squeeze, Breakout and More Instantly...
Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...
SAR443579/IPH6101, ANKET ® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi in R/R AML, B-ALL and HR-MDS SAR443579/IPH6101 continues ...
In heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity regardless of baseline KIR3DL2 expression level. Lacutamab was well-tolerated with a safety profile consistent with prior studies. Innate will host a virtual KOL...